Abstract B62: Potent single agent in vivo activity of the PARP inhibitor veliparib (ABT-888) in <i>BRCA</i>-deficient xenografts (MX-1 and Capan-1).
Cherrie K. Donawho(Abbott Fund), Joann P. Palma(Abbott Fund), Thomas D. Penning(Abbott Fund), Kenneth B. Idler(Abbott Fund), Fritz G. Buchanan(AbbVie (United States)), Vincent L. Giranda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jennifer J. Bouska(Abbott Fund), Velitchka Bontcheva-Diaz(Abbott Fund), Gail Bukofzer(Institute of Cancer Research), Lance Kaleta(Abbott (United States)), Xuesong Liu(Tianjin Institute of Pharmaceutical Research (China)), Robert Carr(Semmelweis University), Gui‐Dong Zhu(Abbott Fund), Alexander R. Shoemaker(Abbott Fund), David J. Frost(Abbott Fund), Luis E. Rodrı́guez(Abbott Fund)
Cited by 1
Related Papers
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776